| Segment Information [Text Block] |
|
15.
|
Segment Information
|
| |
|
| |
The Company’s operations involve the development and usage, including licensing, of its proprietary nutrient infusion Technology. Lexaria is centrally managed and its chief operating decision makers, being the president and the CEO, use the consolidated and other financial information supplemented by revenue information by category of alternative health consumer products and technology licensing to make operational decisions and to assess the performance of the Company. The company has identified two reportable segments: Intellectual Property Licensing and Consumer Products. Licensing revenues are significantly concentrated on a single licensee.
|
| |
IP Licensing
|
Consumer Products
|
Corporate
|
Consolidated Total
|
| External Revenue |
45,809
|
17,830
|
-
|
63,639
|
| CoGS |
-
|
29,750
|
-
|
29,750
|
| Operating Expenses |
360,256
|
120,935
|
1,482,162
|
1,963,354
|
| Segment Loss |
(314,447)
|
(132,856)
|
(1,482,162)
|
(1,929,465)
|
| Total Assets |
62,827
|
69,030
|
2,728,321
|
2,860,178
|
|
|
16.
|
Segment Information
|
| |
|
| |
The Company’s operations involve the development and usage, including licensing, of its proprietary nutrient infusion Technology. Lexaria is centrally managed and its chief operating decision makers, being the president and the CEO, use the consolidated and other financial information supplemented by revenue information by category of alternative health products as well as licensing, as a whole, to make operational decisions and to assess the performance of the Company. Accordingly, the Company operates in a single segment.
|
| |
|
| |
During the year ended August 31, 2015, the Company’s operating segments were the oil and gas exploration and the alternative health products, which were managed separately based on fundamental differences in the nature of such operations.
|
| |
|
| |
Summarized financial information concerning Lexaria’s reportable segment as at and during the year ended August 31, 2015 was as follows:
|
| |
|
|
|
|
|
Alternative |
|
|
|
|
|
|
|
| |
|
|
Oil and Gas |
|
|
Health Products |
|
|
Corporate |
|
|
Total |
|
| |
|
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
| |
Revenue |
|
48,918
|
|
|
14,702
|
|
|
-
|
|
|
63,620
|
|
| |
Operation expenses |
|
-
|
|
|
349,093
|
|
|
1,618,996
|
|
|
1,968,089
|
|
| |
Total assets |
|
-
|
|
|
214,632
|
|
|
497,090
|
|
|
711,722
|
|
|